Literature DB >> 22876085

Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults.

Martin Paspe Cruz.   

Abstract

Entities:  

Year:  2012        PMID： 22876085      PMCID： PMC3411227     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  17 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

3.  Fidaxomicin approved for C. difficile infections.

Authors:  Kate Traynor
Journal:  Am J Health Syst Pharm       Date:  2011-07-15       Impact factor: 2.637

4.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

Review 5.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

Authors:  R Fekety
Journal:  Am J Gastroenterol       Date:  1997-05       Impact factor: 10.864

Review 6.  Clostridium difficile--associated diarrhea.

Authors:  Michael S Schroeder
Journal:  Am Fam Physician       Date:  2005-03-01       Impact factor: 3.292

7.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991.

Authors:  M M Olson; C J Shanholtzer; J T Lee; D N Gerding
Journal:  Infect Control Hosp Epidemiol       Date:  1994-06       Impact factor: 3.254

10.  Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

Authors:  Matthew D Redelings; Frank Sorvillo; Laurene Mascola
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883
View more
  8 in total

1.  Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.

Authors:  Shannon A Novosad; Yi Mu; Lisa G Winston; Helen Johnston; Elizabeth Basiliere; Danyel M Olson; Monica M Farley; Andrew Revis; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Tory Whitten; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Valerie L S Ocampo; Corinne M Davis; Marion Kainer; Dale N Gerding; Alice Y Guh
Journal:  J Gen Intern Med       Date:  2019-11-25       Impact factor: 5.128

2.  Natural products as inspiration for the development of bacterial antibiofilm agents.

Authors:  Roberta J Melander; Akash K Basak; Christian Melander
Journal:  Nat Prod Rep       Date:  2020-07-01       Impact factor: 13.423

3.  Screening for potent and selective anticlostridial leads among FDA-approved drugs.

Authors:  Ahmed AbdelKhalek; Haroon Mohammad; Abdelrahman S Mayhoub; Mohamed N Seleem
Journal:  J Antibiot (Tokyo)       Date:  2020-03-04       Impact factor: 2.649

Review 4.  Fidaxomicin--the new drug for Clostridium difficile infection.

Authors:  Chetana Vaishnavi
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

5.  Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model.

Authors:  Janet Y Nale; Tamsin A Redgwell; Andrew Millard; Martha R J Clokie
Journal:  Antibiotics (Basel)       Date:  2018-02-13

Review 6.  Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.

Authors:  Laith A Al Momani; Omar Abughanimeh; Boonphiphop Boonpheng; Joseph Gabriel Gabriel; Mark Young
Journal:  Cureus       Date:  2018-06-11

7.  Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility.

Authors:  Tri-Hanh-Dung Doan; Stéphanie Yen-Nicolaÿ; Marie-Françoise Bernet-Camard; Isabelle Martin-Verstraete; Séverine Péchiné
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

8.  In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.